AFP and neoplasm: A sum poor prognostic score of the change in intra-tumor blood flow (DA = 0, non-DA = 1), the AFP level (low AFP ratio = 0, high AFP ratio = 1) and remnant liver function (non-liver function deterioration = 0, liver function deterioration = 2) at 2 weeks after the start of sorafenib therapy was calculated.